Residual viraemia is a major obstacle to HIV-1 eradication in subjects receiving HAART. The intensification with raltegravir could impact latent reservoirs and might lead to a reduction of plasma HIV-1 viraemia (viral load [VL]), complementary DNA intermediates and immune activation.
Methods
This was a prospective, open-label, randomized study comprising 69 individuals on suppressive HAART randomly assigned 2:1 to add raltegravir during 48 weeks.
Results
Total and integrated HIV-1 DNA, and ultrasensitive VL remained stable despite intensification. There was a significant increase in episomal HIV DNA at weeks 2–4 in the raltegravir group returning to baseline levels at week 48. Median CD4+ T-cell counts increased 124 and 80 cells/μl in the intensified and control groups after 48 weeks (P=0.005 and P=0.027, respectively), without significant differences between groups. No major changes were observed in activation of CD4+ T-cells. Conversely, raltegravir intensification significantly reduced activation of CD8+ T-cells at week 48 (HLA-DR+CD38+, P=0.005), especially in the memory compartment (CD38+ of CD8+CD45RO+, P<0.0001). Linear mix models also depicted a larger decrease in CD8+ T-cell activation in the intensification group (P=0.036 and P=0.010, respectively). Raltegravir intensification was not associated to any particular adverse event.
Conclusions
Intensification of HAART with raltegravir during 48 weeks was safe and associated with a significant decrease in CD8+ T-cell activation, and a transient increase of episomal HIV-1 DNA. However, raltegravir did not significantly contribute to changes in CD4+ T-cell counts, ultrasensitive VL, and total and integrated HIV-1 DNA. These findings suggest that raltegravir impacts residual HIV-1 replication and support new strategies to impair HIV-1 persistence. ClinicalTrials.gov identifier: NCT00554398.
References
1.
JiangW., LedermanM.M., HuntP.Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis2009; 199: 1177–1185.
2.
LouieM., HoganC., Di MascioM.Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis2003; 187: 896–900.
3.
PerelsonA.S., EssungerP., HoD.D.Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS1997; 11Suppl A: S17–S24.
4.
PerelsonA.S., EssungerP., CaoY.Decay characteristics of HIV-1-infected compartments during combination therapy. Nature1997; 387: 188–191.
5.
RongL., PerelsonA.S.Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLOS Comput Biol2009; 5: e1000533.
6.
BrennanT.P., WoodsJ.O., SedaghatA.R., SilicianoJ.D., SilicianoR.F., WilkeC.O.Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol2009; 83: 8470–8481.
7.
ChunT.W., EngelD., BerreyM.M., SheaT., CoreyL., FauciA.S.Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A1998; 95: 8869–8873.
8.
ZhangL., RamratnamB., Tenner-RaczK.Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med1999; 340: 1605–1613.
9.
DornadulaG., ZhangH., VanUitertB.Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA1999; 282: 1627–1632.
10.
TronoD., Van LintC., RouziouxC.HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science2010; 329: 174–180.
11.
YuklS.A., ShergillA.K., McQuaidK.Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS2010; 24: 2451–2460.
12.
DinosoJ.B., KimS.Y., WiegandA.M.Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A2009; 106: 9403–9408.
13.
GandhiR.T., BoschR.J., AgaE.No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis2010; 201: 293–296.
14.
GandhiR.T., ZhengL., BoschR.J.The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med2010; 7: e1000321.
15.
McMahonD., JonesJ., WiegandA.Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis2010; 50: 912–919.
16.
SedaghatA.R., SilicianoJ.D., BrennanT.P., WilkeC.O., SilicianoR.F.Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog2007; 3: e122.
17.
StepanyukO., ChiangT.S., DeverL.L.Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS2009; 23: 1911–1913.
18.
RamratnamB., RibeiroR., HeT.Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr2004; 35: 33–37.
19.
van PraagR.M., WitF.W., JurriaansS., de WolfF., PrinsJ.M., LangeJ.M.Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS2002; 16: 719–725.
20.
HuntP.W., MartinJ.N., SinclairE.T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis2003; 187: 1534–1543.
21.
GiorgiJ.V., HultinL.E., McKeatingJ.A.Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis1999; 179: 859–870.
22.
HazudaD.J., FelockP., WitmerM.Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science2000; 287: 646–650.
23.
PetitjeanG., Al TabaaY., TuaillonE.Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology2007; 4: 60.
24.
SharkeyM., TriquesK., KuritzkesD.R., StevensonM.In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol2005; 79: 5203–5210.
25.
BuzónM.J., MassanellaM., LlibreJ.M.HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med2010; 16: 460–465.
26.
LandayA., da SilvaB.A., KingM.S.Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis2007; 44: 749–754.
27.
MooreR.D., KerulyJ.C.CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis2007; 44: 441–446.
28.
DeeksS.G.Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med2009; 17: 118–123.
29.
DubéM.P., SattlerF.R.Inflammation and complications of HIV disease. J Infect Dis2010; 201: 1783–1785.
30.
BourgeoisC., HaoZ., RajewskyK., PotocnikA.J., StockingerB.Ablation of thymic export causes accelerated decay of naive CD4 T cells in the periphery because of activation by environmental antigen. Proc Natl Acad Sci U S A2008; 105: 8691–8696.
31.
BrenchleyJ.M., PriceD.A., SchackerT.W.Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med2006; 12: 1365–1371.
32.
CatalfamoM., Di MascioM., HuZ.HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A2008; 105: 19851–19856.
33.
HatanoH., HayesT.L., DahlV.A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis2011; 203: 960–968.
34.
HuntP.W., MartinJ.N., SinclairE.Valganciclovir Reduces T Cell Activation in HIV-infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy. J Infect Dis2011; 203: 1474–1483.
35.
YuklS.A., GianellaS., SinclairE.Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis2010; 202: 1553–1561.
36.
DoitshG., CavroisM., LassenK.G.Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell2010; 143: 789–801.
37.
BullM.E., LearnG.H., McElhoneS.Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol2009; 83: 6020–6028.
38.
CarrJ.M., CheneyK.M., CoolenC.Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy. J Clin Microbiol2007; 45: 1288–1297.
39.
PatelP., HansonD.L., SullivanP.S.Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med2008; 148: 728–736.
40.
FourcadeJ., SunZ., BenallaouaM.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med2010; 207: 2175–2186.
41.
JinH.T., AndersonA.C., TanW.G.Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A2010; 107: 14733–14738.
42.
SakuishiK., ApetohL., SullivanJ.M., BlazarB.R., KuchrooV.K., AndersonA.C.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med2010; 207: 2187–2194.
